Search Results - "Goggin, Timothy"

Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies by De Buck, Stefan S., Jakab, Annamaria, Boehm, Markus, Bootle, Douglas, Juric, Dejan, Quadt, Cornelia, Goggin, Timothy K.

“…Aims The aim was to characterize the population pharmacokinetics of BYL719 in cancer patients and assess the time course of tumour response in relation to drug…”
Get full text

Time‐dependent clearance of mycophenolic acid in renal transplant recipients by Van Hest, Reinier M., Van Gelder, Teun, Bouw, René, Goggin, Timothy, Gordon, Robert, Mamelok, Richard D., Mathot, Ron A.

“…Aims Pharmacokinetic studies of the immunosuppressive compound mycophenolic acid (MPA) have shown a structural decrease in clearance (CL) over time after renal…”
Get full text

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies by Xu, Cong, Goggin, Timothy K., Su, Xiang‐Yao, Taverna, Pietro, Oganesian, Aram, Lowder, James N., Azab, Mohammad, Kantarjian, Hagop

“…Guadecitabine (SGI‐110) is a novel next‐generation hypomethylating agent (HMA) administered as s.c. injection with extended decitabine exposure…”
Get full text

A semimechanistic and mechanistic population PK–PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis by Pillai, Goonaseelan, Gieschke, Ronald, Goggin, Timothy, Jacqmin, Philippe, Schimmer, Ralph C., Steimer, Jean‐Louis

“…Aims Ibandronate, a highly potent nitrogen‐containing bisphosphonate, is the subject of an ongoing clinical development programme that aims to maximize the…”
Get full text

Effect of Hepatic Dysfunction due to Liver Metastases on the Pharmacokinetics of Capecitabine and Its Metabolites by TWELVES, C, GLYNNE-JONES, R, CASSIDY, J, SCHÜLLER, J, GOGGIN, T, ROOS, B, BANKEN, L, UTOH, M, WEIDEKAMM, E, REIGNER, B

“…Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU)…”
Get full text

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients by CASSIDY, J, TWELVES, C, BUSH, E, WEIDEKAMM, E, REIGNER, B, CAMERON, D, STEWARD, W, O'BYRNE, K, JODRELL, D, BANKEN, L, GOGGIN, T, JONES, D, ROOS, B

“…The objective of the study was to assess the bioequivalence of two tablet formulations of capecitabine and to explore the effect of age, gender, body surface…”
Get full text

Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients by REIGNER, B, CLIVE, S, WEIDEKAMM, E, CASSIDY, J, JODRELL, D, SCHULZ, R, GOGGIN, T, BANKEN, L, ROOS, B, UTOH, M, MULLIGAN, T

“…In the present study the possible influence of the antacid Maalox on the pharmacokinetics of capecitabine (Xeloda) and its metabolites was investigated in…”
Get full text

Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction by Lehne, G, Nordal, K P, Midtvedt, K, Goggin, T, Brosstad, F

“…Activation of the platelet membrane receptor glycoprotein (GP) IIb-IIIa is essential for thrombus formation. The novel nonpeptide GPIIb-IIIa antagonist,…”
Get more information

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure by Snoeck, E, Chanu, P, Lavielle, M, Jacqmin, P, Jonsson, E N, Jorga, K, Goggin, T, Grippo, J, Jumbe, N L, Frey, N

“…We propose a model that characterizes and links the complexity and diversity of clinically observed hepatitis C viral kinetics to sustained virologic response…”
Get full text

Population pharmacokinetics and pharmacodynamics of BYL 719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies by De Buck, Stefan S., Jakab, Annamaria, Boehm, Markus, Bootle, Douglas, Juric, Dejan, Quadt, Cornelia, Goggin, Timothy K.

“…Aims The aim was to characterize the population pharmacokinetics of BYL 719 in cancer patients and assess the time course of tumour response in relation to…”
Get full text

Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study by Gonzalez-Angulo, Ana M., Juric, Dejan, Argilés, Guillem, Schellens, Jan HM, Burris, Howard A., Berlin, Jordan, Middleton, Mark R., Schuler, Martin H., Geel, Robin Van, Helgason, Thorunn, Bootle, Douglas, Boehm, Markus, Goggin, Timothy K., Demanse, David, Quadt, Cornelia, Baselga, Jose

“…Abstract only 2531 Background: BYL719 is an oral small-molecule inhibitor of the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is…”
Get full text

Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r‐hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer by Goggin, Timothy, Nguyen, Quyen T. X., Munafo, Alain

“…Aims  The aim of this analysis was to develop a population pharmacokinetic model for Emfilermin (recombinant human leukaemia inhibitory factor, r‐hLIF)…”
Get full text

Pharmacokinetics and pharmacodynamics of Ro 44–3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers by Wittke, Bärbel, Mackie, Ian J., Machin, Samuel J., Timm, Uwe, Zell, Manfred, Goggin, Timothy

“…Aims This study constituted the first administration of the oral platelet inhibitor, sibrafiban, to humans. The aim was to investigate the pharmacokinetics and…”
Get full text

Quality of Life With Three Antihypertensive Treatments: Cilazapril, Atenolol, Nifedipine by Fletcher, Astrid E, Bulpitt, Christopher J, Chase, Dagmar M, Collins, William C.J, Furberg, Curt D, Goggin, Timothy K, Hewett, Andrew J, Neiss, Albrecht M

“…A multicenter, randomized double-blind study of 6 monthsʼ duration was performed in 540 patients (average age 54 years, 57% male) with mild-to-moderate…”
Get full text

Discontinuing antiepileptic drugs

Get more information